Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-B01D1 in patients with Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors.

Trial Details

NCT ID

NCT05983432

Phase

PHASE1

Sponsor

SystImmune Inc.

Status

RECRUITING

Cancer Type

Adenocarcinoma Lung Cancer

Interventions

BL-B01D1

Locations (sample)

Beverly Hills, California, United States|34.07362,-118.40036
Duarte, California, United States|34.13945,-117.97729
Irvine, California, United States|33.66946,-117.82311
Irvine, California, United States|33.66946,-117.82311
Orange, California, United States|33.78779,-117.85311

Key Eligibility Criteria

Signed the informed consent voluntarily and agreed to follow the program requirements
Either sex
Age: ≥18 years
Has a life expectancy of ≥3 months

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Adenocarcinoma Lung Cancer Trials on Trialify →